Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis

Company Overview

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Key Stats

• Today's Range: $3.94 to $4.19
• 50-Day Range: $3.96 to $5.13
• 52-Week Range: $3.85 to $6.75
• Volume: 876,997 shs
• Average Volume: 729,742 shs
• Market Capitalization: $233.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.50
• Consensus Rating: Buy

Vanda Pharmaceuticals Stock Analysis - MarketRank™

Vanda Pharmaceuticals scored higher than 83% of companies evaluated by MarketBeat, and ranked 155th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Vanda Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Vanda Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vanda Pharmaceuticals are expected to grow in the coming year, from ($1.12) to ($0.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vanda Pharmaceuticals is -12.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vanda Pharmaceuticals is -12.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vanda Pharmaceuticals has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.97% of the float of Vanda Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Vanda Pharmaceuticals has a short interest ratio ("days to cover") of 7.4.

Change versus previous month

Short interest in Vanda Pharmaceuticals has recently increased by 21.39%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vanda Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Vanda Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.77

Percentage of Shares Shorted

8.97% of the float of Vanda Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Vanda Pharmaceuticals has a short interest ratio ("days to cover") of 7.4.

Change versus previous month

Short interest in Vanda Pharmaceuticals has recently increased by 21.39%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.59

News Sentiment

Vanda Pharmaceuticals has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 22 news articles for Vanda Pharmaceuticals this week, compared to 4 articles on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Vanda Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $151,180.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 8.90% of the stock of Vanda Pharmaceuticals is held by insiders.

Percentage Held by Institutions

88.14% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VNDA Stock Analysis - Frequently Asked Questions

How have VNDA shares performed this year?

Vanda Pharmaceuticals' stock was trading at $4.79 at the beginning of 2025. Since then, VNDA shares have decreased by 17.3% and is now trading at $3.96.
View the best growth stocks for 2025 here.

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its quarterly earnings data on Wednesday, May, 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.05. The biopharmaceutical company had revenue of $50.04 million for the quarter, compared to analysts' expectations of $45.13 million. Vanda Pharmaceuticals had a negative trailing twelve-month return on equity of 3.49% and a negative net margin of 9.51%.
Read the conference call transcript.

Who are Vanda Pharmaceuticals' major shareholders?

Top institutional shareholders of Vanda Pharmaceuticals include Charles Schwab Investment Management Inc. (0.81%), Monaco Asset Management SAM (0.55%), GSA Capital Partners LLP (0.44%) and Universal Beteiligungs und Servicegesellschaft mbH (0.32%). Insiders that own company stock include Mihael Hristos Polymeropoulos, Kevin Patrick Moran, Joakim Wijkstrom, Timothy Williams, Richard W Dugan and Stephen Ray Mitchell.
View institutional ownership trends.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vanda Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), GE Aerospace (GE), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 5/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VNDA
• CIK: 1347178
• Web: www.vandapharma.com
• Phone: (202) 734-3400
• Fax: 202-296-1450
• Employees: 290
• Year Founded: 2002

Price Target and Rating

• Average Stock Price Target: $16.50
• High Stock Price Target: $20.00
• Low Stock Price Target: $13.00
• Potential Upside/Downside: +316.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-18,900,000.00
• Net Margins: -9.51%
• Pretax Margin: -11.53%
• Return on Equity: -3.49%
• Return on Assets: -2.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.39
• Quick Ratio: 4.37

Sales & Book Value

• Annual Sales: $198.77 million
• Price / Sales: 1.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.23 per share
• Price / Book: 0.43

Miscellaneous

• Outstanding Shares: 58,934,000
• Free Float: 53,126,000
• Market Cap: $233.38 million
• Optionable: Optionable
• Beta: 0.69